All articles tagged with #regulatory review
HealthPartners and Essentia Health have agreed to merge, creating a massive nonprofit healthcare system in the Upper Midwest. The deal, which aims to address rising costs and workforce shortages, faces scrutiny from unions and state regulators.
Warner Bros. Discovery has scheduled an April 23 special shareholders meeting to vote on selling to Paramount Skydance for $31 per share in cash (about a 147% premium). The boards unanimously approved the deal, which is expected to close in Q3 pending regulatory clearances and shareholder approval; if not closed by September 30, shareholders will receive a $0.25 per share quarterly ticking fee. The transaction would create a highly leveraged combined company with expected cost savings, while regulators and lawmakers weigh potential impacts; WBD’s board recommends voting in favor.
An experimental Lyme vaccine from Pfizer and Valneva reduced the risk of Lyme disease by more than 70% in a trial, but it reportedly missed a key statistical endpoint, prompting regulators to scrutinize potential approval amid ongoing debates over trial methods and Lyme prevention.
European publisher Axel Springer agreed to buy Telegraph Media Group for £575m, beating the £500m bid from DMGT. The deal follows a government probe into the DMGT bid and will expand the Telegraph’s footprint, including in the United States, with Springer pledging to invest in growth. Telegraph Media Group (owner of the Daily Telegraph and related outlets) has been ownerless since 2023 due to debts tied to the Barclay brothers; previous approaches by RedBird Capital and others collapsed amid regulatory scrutiny. The deal now awaits regulatory clearance and marks Springer's largest acquisition since buying Politico in 2021.
The European Commission is set to conduct a multi-stage antitrust review of Paramount's $110 billion deal to merge with Warner Bros. Discovery, a process expected to slow the transaction more than block it. After a 25-working-day preliminary check, Brussels could launch a Phase II review, potentially stretching the timeline beyond a year. The EU will scrutinize overlaps across cinema distribution, TV channels, and streaming platforms, and may require divestitures; the UK review might be simpler. Financing from Middle Eastern funds and the EU's foreign subsidies rules add another layer of scrutiny. Overall, while approval remains likely, EU hurdles could push the close further out than in the U.S.
Paramount and Warner Bros. Discovery officially announce a $111 billion merger, backed by $47 billion in equity from the Ellison family and RedBird Capital and $54 billion in debt financing, with Netflix previously in the mix but now out. The deal aims to close in Q3 2026, keeps both studios independent with promised output and windows, and is expected to yield about $6 billion in synergies, while regulators review the transaction and Hollywood braces for layoffs.
California Attorney General Rob Bonta said his office will conduct a vigorous review of Paramount Skydance’s planned acquisition of Warner Bros. Discovery, warning the deal isn’t a done deal and that the California Department of Justice has an open investigation. The note comes as the bid saga swirls with shifting offers and Netflix exiting the bidding, underscoring heightened regulatory scrutiny of entertainment industry consolidation.
Moderna says the FDA will review its experimental mRNA-based flu vaccine after resolving a public dispute, signaling movement toward potential regulatory consideration of the shot.
The FDA reversed its initial refusal to accept Moderna’s seasonal flu vaccine filing after a White House meeting in which President Trump pressed the agency, with Moderna submitting an amended filing and the FDA agreeing to review it via a Type A meeting. The agency accepted the application for full approval for adults 50–64 and accelerated approval for 65+, with a post‑marketing study to address age-related concerns, and a target decision date of August 5, 2026.
Warner Bros. Discovery is at the center of a Hollywood rivalry, with Netflix proposing a $72 billion deal and Paramount pursuing a $77.9 billion hostile takeover, both facing lengthy regulatory hurdles that could reshape the media landscape, impact competition, and involve political considerations, including potential influence from the Trump administration.
The largest U.S. railroad union endorses Union Pacific's $85 billion merger with Norfolk Southern after securing job protections, though some unions and industry groups remain concerned about competition and service disruptions. The deal has mixed support among unions and faces a lengthy regulatory review, with President Trump's stance potentially influencing the outcome.
The Trump administration is considering strict new restrictions on licensing Chinese investigational drugs, including enhanced scrutiny and security reviews, amid concerns over China's growing influence in biotech and medicine, with proposals also to boost US domestic drug production and speed up FDA review processes.
The FDA's top cancer drug regulator, Richard Pazdur, played a key role in the rejection of Replimune's skin cancer therapy, RP1, amid internal agency dysfunction and leadership changes, despite support from other officials. The decision was influenced by internal debates and procedural issues within the FDA.
The FDA has launched its agency-wide AI tool, Elsa, ahead of schedule, aiming to streamline clinical protocol reviews and speed up regulatory processes, as highlighted by Commissioner Marty Makary.
JetBlue and United have announced a partnership featuring a frequent flyer program, elite benefits, and interline sales, with United returning to JFK in 2027 and sharing slots with JetBlue. The deal also includes United adopting JetBlue's Paisly for travel services and both airlines leveraging Kinective for advertising. While not a joint sales agreement, the partnership aims to enhance their market offerings and corporate deals, with regulatory approval still pending.